VANCOUVER, British Columbia, June 29, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Citigroup (NYSE:C), Tenet Healthcare (NYSE:THC), Vertex Pharmaceuticals (NASDAQ:VRTX), Barclays (NYSE:BCS), NVIDIA (NASDAQ:NVDA), and Genworth Financial (NYSE:GNW).
(Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)
Report Highlights:
Citigroup Inc. (NYSE:C): Recently, Citigroup Inc. (NYSE:C) promoted Hong Kong-based Jonathan Larsen as global Head of its retail bank. Larsen will remain his role of Head of consumer banking for the Asia-Pacific region. In the last trading session, Citigroup shares dipped as much as 2.62% to US$26.39, which was up 23% from its 52-week low price. The stock traded 68.24 million shares, well above its daily average of 43.10 million shares. Where do you think Citigroup will go from here? Academic studies clarify that professional investors can get benefit from insider trading data. Do you want to trace Citigroup Inc. on an on-going basis? It can be done for free by registering below.
Read Full Report: http://www.insiderslab.com/PR3/062912B/C/Citigroup.pdf
Tenet Healthcare Corporation (NYSE:THC): Tenet Healthcare Corporation (NYSE:THC) trades have gone up 5.42% to US$5.25 with heavy volume traded, which was 7.4 times more than usual. In the past 52 weeks, Tenet Healthcare share prices have been bracketed by a low of US$3.46 and a high of US$6.54, and are now at US$5.25 which was up 52% from its 52-week low price. Tenet Healthcare Corporation is an investor-owned health care services company with a market capitalization of US$2.17 billion. Do you think the stock will continue to increase? Do you think now is a good time to exercise or sell Tenet Healthcare? Professional investors could get an idea by checking this insider trade report for THC here.
Read Full Report: http://www.insiderslab.com/PR3/062912B/THC/TenetHealthcare.pdf
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): Insiderslab.com found Market Option Sale (Planned) made by company Director -- Joshua S. Boger, Ph.D. on June 20, at stock price US$58.09. Disclose date: June 22. In May, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced interim results about its cystic fibrosis drug Kalydeco, which have strong positive improvement in lung function among patients. Still, in the report of Vertex announced on Thursday, Jun 28, the company stated that Kalydeco may not be as effective as the interim data had implied. By market close, Vertex Pharmaceuticals shares slumped US$9.93 per share (equivalent to 16.25%), where stock prices dropped to US$51.18. There were 19.49 million stock shares traded, which was 5.7 times more than average volume.
Read Full Report: http://www.insiderslab.com/PR3/062912B/VRTX/VertexPharmaceuticals.pdf
Today Insiderslab.com also observed abnormal trade volume for the following companies; insiders may involve trading in these companies. It will take some time for insiders to report their trades. Read these reports and add these companies into your Insider Trade Radar.
Barclays PLC (ADR) (NYSE:BCS):
Read Full Report: http://www.insiderslab.com/PR3/062912B/BCS/Barclays.pdf
NVIDIA Corporation (NASDAQ:NVDA):
Read Full Report: http://www.insiderslab.com/PR3/062912B/NVDA/NVIDIA.pdf
Genworth Financial Inc. (NYSE:GNW):
Read Full Report: http://www.insiderslab.com/PR3/062912B/GNW/GenworthFinancial.pdf
Insider Filing Source Reference: All observations, analysis and reports are based on public information released by the U.S. Securities and Exchange Commission.
About Insiderslab.com:
Insiderslab.com covers insider trade data in major stock markets in the U.S., Hong Kong, Mainland China, and Singapore. Insiderslab.com features a team of experienced data analysts striving to provide the investment community with the tools, software, and data necessary to carry out more effective investment research.
Important Disclaimer:
Please visit insiderslab.com/disclaimers/disclaimers.php for details.
